SITC News

SITC is pleased to announce the publication of a new manuscript titled “A SITC Strategic Vision: Prevention, Premalignant Immunity, Host and Environmental Factors,” available now in the Journal for ImmunoTherapy of Cancer ( JITC ). This manuscript is the third in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer, which outlines the current state of the field, elevates the most pressing challenges, and proposes the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of ...

SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting Celebrating 40 years of driving breakthroughs in cancer immunotherapy MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Jennifer A. Wargo, MD, MMSc, from The University of Texas MD Anderson Cancer Center as the Keynote Speaker at its 40 th Anniversary Annual Meeting and Pre-Conference Programs (SITC 2025) with her presentation “Targeting the Microbiome to Promote Health and End Cancer.” SITC also hosts Ira Mellman, PhD, FAACR, ...

In celebration of the 40 th Anniversary of the Society for Immunotherapy of Cancer (SITC), the Journal for ImmunoTherapy of Cancer ( JITC ) presents this special series of commentaries from luminaries in the field of immuno-oncology. Numerous SITC Fellows of the Academy of Immuno-Oncology and Richard V. Smalley Memorial Award recipients put pen to paper to provide their insights into current achievements in various areas of the field while also sharing their personal, forward-looking vision of where the field is moving in the upcoming decades. As SITC looks forward with anticipation of exciting ...

SITC’s 2025 Capitol Hill Visits have officially concluded after engaging with over 25 congressional offices! During these meetings, SITC members passionately advocated for the inclusion of SITC’s FY26 appropriations language, emphasizing the need for utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. We extend our sincere thanks to all the SITC members who volunteered their time and expertise to participate. We couldn't do this without you! See SITC’s full FY26 language HERE . ...

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 AACR Annual Meeting. 2025 Scientific Highlights Addition of perioperative pembrolizumab to the standard of care significantly improves event free survival in patients with head and neck squamous cell carcinoma CT001. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study Ravindra Uppaluri (Brigham and ...

Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) strongly opposes the recent actions asking for a significant reduction in staff at the Department of Health and Human Services (HHS). As an organization dedicated to advancing the science and application of cancer immunotherapy to make the word "cure" a reality for patients, SITC is deeply concerned that these cuts are already resulting in profound and detrimental impact on the United States' research and development ecosystem, delaying the progress of life-saving therapies to those who need them most. One of the most ...

SITC is pleased to announce the kickoff of SITC’s 2025 in person Capitol Hill Visits! Over the last few months SITC members have been meeting virtually with congressional offices all across the country to advocate for inclusion of SITC’s FY26 appropriations language aimed at utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. These meetings have served as important opportunities for SITC to share the impact cancer immunotherapy has had on the field, and the critical need for further support ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...

Manuscript Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting. The new RCC ...

Manuscript Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting. The new RCC manuscript ...

SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will ...

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will ...

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances ...

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances ...

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks ...

INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks ...

A Message from the President For 40 years, the Society for Immunotherapy of Cancer (SITC) has ...

A Message from the President During this period of significant change within the U.S. federal ...

A Message from the President Over the last 12 months, you collectively dedicated your creativity, ...